Tongxinluo Capsule Combined with Atorvastatin for Coronary Heart Disease: A Systematic Review and Meta-Analysis

Introduction. Coronary heart disease (CHD) is a common clinical cardiovascular disease, and its morbidity and mortality rates are increasing, which brings a serious burden to the family and society. Dyslipidemia is one of the most important risk factors for CHD. However, it is difficult to reduce bl...

Full description

Saved in:
Bibliographic Details
Published in:Evidence-based complementary and alternative medicine 2021, Vol.2021, p.1-17
Main Authors: Liu, Qiao, Dong, Taiwei, Xi, Miaomiao, Gou, Licheng, Bai, Yang, Hou, Lian, Li, Min, Ou, Li, Miao, Feng, Wei, Peifeng
Format: Article
Language:English
Subjects:
Adverse events
Angina
Angina pectoris
Atherosclerosis
Atorvastatin
Bias
C-reactive protein
Cardiovascular disease
Cardiovascular diseases
Chinese medicine
Cholesterol
Clinical medicine
Clinical trials
Coronary artery disease
Dyslipidemia
Electrocardiography
Heart attacks
Heart diseases
Heart failure
High density lipoprotein
Inflammation
Lipids
Lipoproteins
Low density lipoprotein
Medical research
Meta-analysis
Morbidity
Quality control
Review
Reviews
Risk factors
Statins
Systematic review
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Introduction. Coronary heart disease (CHD) is a common clinical cardiovascular disease, and its morbidity and mortality rates are increasing, which brings a serious burden to the family and society. Dyslipidemia is one of the most important risk factors for CHD. However, it is difficult to reduce blood lipids to an ideal state with the administration of a statin alone. Tongxinluo capsule (TXLC), as a Chinese patent medicine, has received extensive attention in the treatment of CHD in recent years. This systematic review and meta-analysis aim to provide evidence-based medicine for TXLC combined with atorvastatin in the treatment of CHD. Objective. To evaluate systematically the effectiveness and safety of TXLC combined with atorvastatin in the treatment of CHD. Methods. Seven English and Chinese electronic databases (PubMed, Cochrane Library, Embase, CNKI, VIP, CBM, and Wanfang) were searched from inception to January 2020, to search for randomized controlled trials (RCTs) on TXLC combined with atorvastatin in the treatment of CHD. Two researchers independently screened the literature according to the literature inclusion and exclusion criteria and performed quality assessment and data extraction on the included RCTs. We performed a systematic review following Cochrane Collaboration Handbook and Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and using a measurement tool to assess the methodological quality of systematic reviews (AMSTAR 2). The quality of outcomes was evaluated by the Grading of Recommendations Assessment, Development and Evaluation (GRADE). And meta-analysis was performed by Review Manager 5.2. Results. A total of 15 RCTs with 1,578 participants were included in this review. Compared to atorvastatin treatment, TXLC combined with atorvastatin treatment showed potent efficacy when it came to the effectiveness of clinical treatment (RR = 1.24; 95% CI, 1.18, 1.29; P
ISSN:1741-427X
1741-4288
DOI:10.1155/2021/9413704